There is compelling need to focus on Biosimilar from govt, patients' point of view: Kiran Mazumdar-Shaw
There is a compelling need to focus on Biosimilar from govt and patients' point of view. Biocon and Mylan are leading the way along with few others in the Biosimilars segment, says Kiran Mazumdar-Shaw of Biocon limited.
Other Biotech Videos
AI in Pharma: How India's Drug Giants Are Betting Big on Artificial Intelligence
USV | Take heart: Steering preventive strategies for charting a journey towards cardiac wellness
Beat Diabetes With Lifestyle Modification
Serum to double investment in Biocon's unit to $300 mn; aim to generate higher EBITDA going ahead: Kiran Mazumdar-Shaw
India is stepping up genome sequencing of COVID 19 positive samples amid growing outbreaks in China, Japan and South Korea
